Biography:Behnam Badie, M.D., an expert in the field of surgical neuro-oncology, is the director of the Brain Tumor Program and the Division of Neurosurgery at the City of Hope National Medical Center. Dr. Badie has special interest in the treatment of skull base tumors, acoustic neuromas, pituitary tumors, meningiomas and other nervous system tumors. His clinical research is in the development of minimally invasive techniques for treatment of both benign and malignant brain tumor. Dr. Badie earned his medical degree and completed an internship and residency at the University of California Los Angeles. Prior to joining the Department of Neurosurgery, Dr. Badie was an Associate Professor and vice-chair of the Department of Neurological Surgery at the University of Wisconsin in Madison where he also served as the director of the Comprehensive Brain Tumor Program. Dr. Badies research interests focus on brain tumor immunology. More specifically, his research team is attempting to develop novel immunotherapy approaches for malignant brain tumors through the activation of microglia and macrophages using nanoparticles. This research is currently funded by the NCI and other organizations. Dr. Badie has published more than 140 articles, book chapters and abstracts in peer-reviewed journal. He is an active member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, Society of Neuro-oncology, and others.

Biography:Neurologist Chad M. Miller, MD, is a neurocritical care and stroke specialist in the Department of Neurology at Cedars-Sinai Medical Center. He is board certified in neurocritical care and is a diplomat of the American Board of Psychiatry and Neurology. Before joining Cedars-Sinai, Dr. Miller was on faculty as an assistant professor in the Department of Neurosurgery at the David Geffen School of Medicine at the University of California, Los Angeles.
Dr. Millers clinical practice and research focuses on the care of stroke and intracerebral hemorrhage patients, as well as those with spinal cord injury, seizure disorders, traumatic brain injury, and subarachnoid hemorrhage. He has spoken at medical centers and universities across the country on issues related to neuro-critical care and stroke. He has published extensively in peer-reviewed journals, including Critical Care Medicine, Neurocritical Care, Surgical Neurology and Neurosurgery, as well as having written several book chapters. Dr. Miller is a member of the American Academy of Neurology, the American Stroke Association and the Neurocritical Care Society.
Dr. Miller earned a bachelors degree from Miami University, and his medical degree from The Ohio State University. He then completed a residency in adult neurology at Duke University Medical Center and a fellowship in neurosurgical critical care at the UCLA Medical Center.

Biography:Dr. Henchcliffe trained at Oxford University UK, where she completed her doctorate in
molecular and cell biology prior to post-doctoral neuroscience research at the University
of California at Berkeley. She received her medical degree from the College of
Physicians and Surgeons of Columbia University, New York. She completed Neurology
residency and Movement Disorders Fellowship at the New York Presbyterian Hospital,
under the guidance of Dr Stanley Fahn. After fellowship, she moved to the Weill Medical
College of Cornell University, New York, where she established and is Director of the
Weill Cornell Parkinsons Disease and Movement Disorders Institute. She is now
Associate Professor of Neurology and Neuroscience. She provides clinical care for
patients with movement disorders including Parkinsons disease, Progressive
Supranuclear Palsy, Corticobasal Degeneration, and other conditions. She is a member of
numerous medical organizations including the American Academy of Neurology and the
Parkinson Study Group. She frequently teaches and writes on Parkinsons disease, and
her team run multiple clinical trials. Her own research interests are in developing new
pharmacologic and non-pharmacologic treatments, including exercise based therapy, and
the possibility of stem cell therapy, and in biomarker development particularly as applied
to trial outcomes.